Front-line hospital practices are facing a formidable adversary: common infections that no longer respond to mainstay antibiotics. New warnings from the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) highlight surging rates of antimicrobial resistance, describing the threat as worse now than before the pandemic and effective treatments for some patients as exhaustible.
Bacteria such as Klebsiella pneumoniae, once managed with standard therapies, are now regularly defeating multiple lines of drugs in hospitals across Europe, WHO reported on November 18, 2026. Instead of achieving a targeted five percent reduction in infections caused by this bacterium, cases rose an estimated 72 percent between 2019 and 2025. The pattern repeats for E. coli infections resistant to first-choice cephalosporin antibiotics: instead of decreasing ten percent as planned, infections climbed more than sixteen percent.
The consequences are acute: about half of the Klebsiella and Acinetobacter samples tested from European countries in the latest analysis showed resistance to both common and so-called ‘last-resort’ antibiotics. As Dr. Marc-Alain Widdowson of WHO/Europe stressed, conventional treatments are often failing, forcing doctors to rely on very costly and less accessible drugs with more severe side effects—and sometimes, ‘patients move closer to having no good options at all.’ People whose initial antibiotic fails are notably more likely to die during hospitalization.
Challenges in the fight against these superbugs go beyond resistant organisms themselves. WHO found that in hospitals where few blood samples are collected to identify specific bacteria, doctors must select treatments ‘half-blind.’ This practice increases the chances of starting with ineffective drugs and clouding the bigger epidemiological picture. Sixteen of 51 countries still lack coordinated national strategies against antimicrobial resistance, weakening containment efforts and data collection.
In the United States, the latest CDC Antimicrobial Resistance Threats Report reveals more than 9.3 million drug-resistant infections occur annually, leading to over 39,000 deaths. When factoring in cases of Clostridioides difficile, whose spread is driven by antibiotic misuse even though it’s not a resistant bacterium itself, U.S. deaths nearly reach 51,000 per year. Globally, WHO and CDC estimate antimicrobial resistance causes more than one million deaths directly, with nearly five million deaths associated as of 2019.
At the microbial level, resistance develops through numerous defense strategies. Some bacteria bar antibiotics from entry, actively eject them, or use enzymes—such as carbapenemases in Klebsiella pneumoniae—to destroy even the most potent drugs. These genetic traits can be handed off between germs, accelerating the spread and diversity of resistance in healthcare, agriculture, and in the community. Resistance to even a single drug can force clinicians into costly or toxic treatment regimens, sometimes with no viable therapy remaining.
Amid troubling data, there are indications some threats can be contained by coordinated efforts. WHO observes the rate of drug-resistant Acinetobacter bloodstream infections in Europe has nearly halved from COVID-19 pandemic highs. Yet this progress remains brittle, with the pandemic itself responsible for a 20 percent surge in six types of drug-resistant hospital infections in the U.S., knocking back hard-won gains.
Experts from both WHO and CDC agree: with resistance emerging worldwide and able to cross borders rapidly, only more robust surveillance, better testing, and prudent use of antibiotics can slow the tide. The mismatch between goals and outcomes in Europe, and the heavy toll in the U.S., underline that without globally coordinated action, antimicrobial resistance may continue outpacing both science and public health responses. For now, patients in many of the world’s hospitals are watching their treatment options dwindle, as the race continues for effective answers.